{
  "id": 12453909,
  "title": "Tumor markers reveal which HER2+ breast cancer patients may respond to less intensive chemotherapy",
  "url": "https://urgent.news/2026/10/06/tumor-markers-reveal-which-her2-breast-cancer-patients-may-respond-to",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-06T19:20:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-tumor-markers-reveal-her2-breast.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "The Journal of Clinical Oncology has published secondary results from the ECOG-ACRIN Cancer Research Group's CompassHER2-pCR clinical trial (EA1181, NCT04266249). The findings help identify which early-stage HER2-positive (HER2+) breast cancers may be most likely to respond to less intensive chemotherapy than the current standard.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}